- Home
- SRTS vs BOLD Comparison
SRTS vs BOLD Comparison
Compare SRTS & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRTS
- BOLD
- Stock Information
- Founded
- SRTS 2010
- BOLD 2018
- Country
- SRTS United States
- BOLD United States
- Employees
- SRTS N/A
- BOLD N/A
- Industry
- SRTS Medical/Dental Instruments
- BOLD
- Sector
- SRTS Health Care
- BOLD
- Exchange
- SRTS Nasdaq
- BOLD Nasdaq
- Market Cap
- SRTS 118.2M
- BOLD 59.8M
- IPO Year
- SRTS 2016
- BOLD 2024
- Fundamental
- Price
- SRTS $6.64
- BOLD $2.30
- Analyst Decision
- SRTS Strong Buy
- BOLD Buy
- Analyst Count
- SRTS 2
- BOLD 3
- Target Price
- SRTS $12.50
- BOLD $22.50
- AVG Volume (30 Days)
- SRTS 244.3K
- BOLD 122.2K
- Earning Date
- SRTS 02-06-2025
- BOLD 11-07-2024
- Dividend Yield
- SRTS N/A
- BOLD N/A
- EPS Growth
- SRTS N/A
- BOLD N/A
- EPS
- SRTS 0.57
- BOLD N/A
- Revenue
- SRTS $41,308,000.00
- BOLD N/A
- Revenue This Year
- SRTS $65.04
- BOLD N/A
- Revenue Next Year
- SRTS $24.87
- BOLD N/A
- P/E Ratio
- SRTS $11.51
- BOLD N/A
- Revenue Growth
- SRTS 65.62
- BOLD N/A
- 52 Week Low
- SRTS $2.61
- BOLD $2.19
- 52 Week High
- SRTS $9.33
- BOLD $15.24
- Technical
- Relative Strength Index (RSI)
- SRTS 37.42
- BOLD N/A
- Support Level
- SRTS $6.38
- BOLD N/A
- Resistance Level
- SRTS $7.62
- BOLD N/A
- Average True Range (ATR)
- SRTS 0.44
- BOLD 0.00
- MACD
- SRTS -0.07
- BOLD 0.00
- Stochastic Oscillator
- SRTS 19.70
- BOLD 0.00
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.